April 12, 2017
CEO Message to Shareholders (from 2016 Annual Report)
DearShareholders, It’s remarkable the difference one year can make. I’d like to tell you how we felt upon learning of the negative KIACTATM Phase 3 AA amyloidosis results in mid 2016, how we decided to rebuild from this bitter disappointment and why we are more excited than ever about the future-particularly because of our new project, BLU-5937. Shocked and disappointed. From our partners at...
April 8, 2016
CEO Message to Shareholders (from 2015 Annual Report)
Dear Shareholders, We have made important progress in our business plan in 2015 that has setup the coming year to be one of the most important in our Company history. Developing Rare Disease Drugs is a Growing Trend Regulatory agencies, and particularly the US Food and Drug Administration (FDA), are increasingly approving innovative drugs and in particular drugs that treat rare diseases. Last...